Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Kudoh, Shinzoh; Takeda, Koji; Nakagawa, Kazuhiko; Takada, Minoru; Katakami, Nobuyuki; Matsui, Kunihiko; Shinkai, Tetsu; Sawa, Toshiyuki; Goto, Isao; Semba, Hiroshi; Seto, Takashi; Ando, Masahiko; Satoh, Taroh; Yoshimura, Naoki; Negoro, Shunichi; Fukuoka, Masahiro

doi:10.1200/jco.2006.06.1044

Cited by 336 publications

(211 citation statements)

References 21 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Indeed a statistically significant advantage in terms of progression-free survival (5.5 vs 3.1 months), response rate (22.7 vs 9.9%), and improvement of disease-related symptoms was observed in favour of docetaxel; docetaxel had a nonsignificantly prolonged median overall survival (14.4 vs 9.9 months) (Kudoh et al, 2006). In the first line setting, docetaxel demonstrated both an interesting activity and efficacy whether combined with a platinum compound (Fossella et al, 2003) or with gemcitabine.…”

mentioning

confidence: 93%

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

Tibaldi¹,

Vasile²,

Antonuzzo

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

This multicenter phase II study evaluated, in chemonaive patients with stage IIIB -IV NSCLC, age X70 and with a performance status 0 -2, the activity, efficacy and tolerability of planned sequential administration of gemcitabine 1200 mg m À2 on days 1 and 8 every 3 weeks for three courses followed by three cycles of docetaxel 37.5 mg m À2 on days 1 and 8 every 3 weeks, provided there was no evidence of disease progression. A total of 56 patients entered the study. According to intention-to-treat analysis, the objective response rate was 16.0% (95% CI 7.6 -28.3%); 23 patients (41.0%) had stable disease and 24 patients (43%) had progressive disease. Five patients who had a stable disease after three courses of gemcitabine obtained a conversion to partial response by docetaxel. Median time to progression was 4.8 months (95% CI 3.6 -6.0 months) and median duration of survival was 8.0 months (95% CI 5.6 -10.5 months). The 1-year survival rate was 34%. No grade 4 haematological toxicity was observed and grade 3 neutropenia and thrombocytopenia were reported in 5.4 and 3.6% of the patients, respectively. Grade 3/4 mucositis and grade 3 diarrhoea, both occurred in 3.6% of the patients and grade 3 asthenia was observed in 9% of patients. One patient reported a grade 4 skin toxicity. No treatment-related deaths occurred. Sequential gemcitabine and docetaxel is a well-tolerated and effective regimen in elderly advanced NSCLC patients.

show abstract

mentioning

confidence: 93%

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

Tibaldi¹,

Vasile²,

Antonuzzo

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…6,7,11 Recently, two randomized Phase III trials evaluated the efficacy of was terminated early (JCOG0803/WJOG4307L). 13 In this trial, the combination regimen was again more toxic.…”

Section: Discussionmentioning

confidence: 99%

“…14 showed that toxicities were more severe in the subset containing patients ≥ 75 years of age compared with the younger subset. 11 In the JCOG0803/WJOG4307L trial, three quarters of patients recruited were ≥ 75 years of age. This study evaluated the cisplatin combination regimen, and the older subgroup showed severe toxicities.…”

Section: Discussionmentioning

confidence: 99%

Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer

Takatani

Nakamura

Nagashima

et al. 2012

Clinical Lung Cancer

View full text Add to dashboard Cite

show abstract

“…A recent phase III study compared docetaxel with vinorelbine in older patients with NSCLC [30]. Previously untreated patients (n ϭ 182; median age, 76 years; range, 70 -86 years) with advanced NSCLC were randomized to treatment with either docetaxel, 60 mg/m 2 on day 1 of a 21-day cycle (n ϭ 92), or vinorelbine, 25 mg/m 2 on days 1 and 8 (n ϭ 92).…”

Section: Phase III Studiesmentioning

confidence: 99%

The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

Ramalingam

Khuri

2009

The Oncologist

View full text Add to dashboard Cite

The treatment of older patients with advanced nonsmall cell lung cancer (NSCLC) represents a considerable challenge for physicians. A patient's suitability for chemotherapy is frequently based solely on chronologic age; as a consequence, older patients with NSCLC are less likely to receive standard chemotherapy than younger patients. Although age-related factors, such as comorbid illness, should be taken into consideration when assessing a patient's suitability for treatment, fit and functionally independent older patients should be considered candidates for standard chemotherapy. The taxanes are widely used in the treatment of advancedstage NSCLC and are well tolerated in older patients. The efficacy of both paclitaxel and docetaxel has been studied in older patients and appears to be comparable with that seen in younger patients either as monotherapy or in combination with a platinum compound as first-line therapy. In addition to the available evidence, prospective evaluation of novel agents in elderlyspecific or -enriched studies is necessary to guide the treatment of older patients with NSCLC. The Oncologist

show abstract

Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

Cited by 336 publications

References 21 publications

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer

The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About